The patient comes first
For Bayer, one of the world's leading specialty pharmaceutical companies, patients' health always comes first. Exchanging ideas and information with patient organizations on the basis of mutual trust is an important component of our work.
Such cooperation helps us to understand the needs of patients as they come to terms with their illness. This enables us to gear our research and development to these needs and to continue working on improved, new drugs and therapies.
Bayer cooperates with patient organizations in all kinds of therapeutic areas. We attach great importance to transparency in this context and protect the independence of our cooperation partners.
Cooperation between Bayer and patient organizations is based on the following principles.
- In order to provide patients with quality medical healthcare, a partnership with a patient organization pursues a specific objective concentrating on one or more of the following areas:
- raising awareness for certain diseases by improving diagnostic possibilities and preventive measures, knowing the patients' prospects and needs,
- understanding diseases and making sure that patients receive the best medical treatment available,
- improving the information provided to the patients,
- supporting medical innovations.
- Bayer and the patient organizations comply with international and national laws and regulations.
- Cooperation with a patient organization should neither influence decisions on a therapy nor promote or support specific therapies.
- Bayer respects the neutrality and independence of patient organizations. Cooperation is based on a partnership between equals in which transparency and clarity are fundamental principles. This is why we also provide information on the extent and nature of support.
Overview of cooperation with patient organizations in Europe in 2015
The following is a list of patient organizations with which Bayer and its affiliated companies in Europe cooperated in 2015.
|Patient Organizations||Country of Organization's Office||Nature and Purpose of Support||Value in Euro||Travel costs|
|Cittadinanzattiva||Italy||Support of the organization's multi-sponsored "9th European Patient's Rights Day" in Brussels, May 12, 2015||10,000||no|
|Deutsche Diabetes-Hilfe - Menschen mit Diabetes (DDH-M)||Germany||Presentation for Bayer at a press event on September 17, 2015 in Nice, France||no||242,98|
|Deutscher Blinden- und Sehbehindertenverband e. V.||Germany||Presentation for Bayer at a press event on September 17, 2015 in Nice, France||no||561,02|
|Deutscher Blinden- und Sehbehindertenverband e. V.||Germany||Presentation for Bayer at a press event on September 17, 2015 in Nice, France||no||222,58|
|ELPA (European Liver Patients Association)||Belgium||Support of PO to send one representative to the Bayer advocacy round table, Chicago (USA) June 1, 2015 with Bayer senior management and international patient advocates to exchange on how to best address challenges in patient access to innovative care, best practice on working collaboratively around patient needs and communication methods||no||5978,72|
|ELPA (European Liver Patients Association)||Belgium||Support of PO to send one representative to the Bayer Advisory Board Meeting "Patient Clinical Trial Education and Information", Whippany (USA) April 4, 2015, to provide the patient advocate perspective on patient's experiences with clinical trial information||no||4626,74|
|EuropaColon||UK||Support core and project activities of PO in 2015, including policy round tables, patient unmet objective need analysis and patient education activities||50,000||no|
|EuropaUomo||Belgium||Support of PO to send one representative to the Bayer Advisory Board Meeting "Patient Clinical Trial Education and Information", Whippany (USA) April 9, 2015, to provide the patient advocate perspective on patient's experiences with clinical trial information||no||5101,43|
|European Alliance for Personalised Medicine||Belgium||Annual Partnership for continued collaboration / "STEPs in the Right Direction" initiative on an EU policy level||40,000||no|
|European Haemophilia Consortium (EHC)||Belgium||Sponsorship of Annual Conference of EHC (2015)||25,500||no|
|European Haemophilia Consortium (EHC)||Belgium||Membership of the EHC's Corporate Giving Program and EHC's Round Tables||40,000||no|
|European Multiple Sclerosis Platform (EMSP)||Belgium||Financial support of PO’s key projects: EMSP's Annual Spring Conference, MS Nurse, PRO online training, European awareness raising campaign "Under Pressure" and European MS Register EUReMS.||50,000||no|
|European Society of Gynaecological Oncology (ESGO)||Switzerland||Support core and project activities of PO regarding the ENGAGe initiative of ESGO in 2015, including patient seminars, development and dissemination of educational resources||30,000||no|
|EURORDIS||France||Support PO regarding their activities in building initiatives to break the isolation of rare disease patients and their families in Europe including PO’s fundraising dinner in 2015 and communication activities associated with this event||35,000||no|
|Federazione A.L.I.Ce. Italia Onlus||Italy||Support of the organization's activities regarding education and awareness raising on the subject of stroke and atrial fibrillation||80,238||no|
|FEND (Foundation of European Nurses in Diabetes)||UK||Support of the 20th annual FEND conference, September 11-12, 2015 in Stockholm (Sweden)||15,000||no|
|Fundacja Udaru Mózgu||Poland||Support of awareness-related activities regarding the Atrial Fibrillation Patient Charta as part of the organization's campaign "Prevent Stroke"||18,400||no|
|German Working Group on Castration-Resistant Prostate Cancer e.V.||Germany||Support of Development of a patient White Book on bone health and MetastaticCastration-resistant Prostate Cancer (mCRPC)||22,000||no|
|IAPB Trading Ltd. (London School of Hygiene & Tropical Medicine)||UK||Support of the World Sight Day and Council of Members Meeting 2015||35,511||no|
|International Agency for the Prevention of Blindness (IAPB)||UK||Support in advocating the implementation of the Universal Eye Health and the Global Action Plan within member countries and in managing the learning and development program for VISION 2020||88,779||no|
|International Diabetes Federation||Belgium||Support of PO and continued engagement Diabetic Retinopathy (DR) Barometer activities and secondary data analysis and publication||72,145||no|
|International Kidney Cancer Coalition (IKCC)||Germany||Support of the 5th annual conference, Morristown (USA), April 16-18, 2015||42,000||no|
|International Planned Parenthood Federation European Network (IPPFEN)||Belgium||Support of PO regarding launch, communication and policy activities of the publication of the 2015 edition of the Barometer on "Women's Access to Modern Contraceptive-Choice-in the EU"||85,000||no|
|Myeloma UK||UK||Support of PO to send one representative to the Bayer advocacy round table, Chicago (USA) June 1, 2015 with Bayer senior management and international patient advocates to exchange on how to best address challenges in patient access to innovative care, best practice on working collaboratively around patient needs and communication methods||no||yes|
|PHA Europe||Austria||Support for their advocacy work, their annual general meeting and their fellowship program in 2015||120,000||no|
|PHA Europe||Austria||Support of patient organisation's campaign to raise a broader awareness around World Pulmonary Hypertension Day (WPHD (incl. support “IronMan 2015” in Frankfurt||25,000||no|
|PHA Europe||Austria||Support of PO regarding EU Policy Campaigns related to Pulmonary Hypertension||50,000||no|
|PHA Europe||Austria||Presentation at the 6th International Nurse Forum, July 2015||no||489,27|
|PHA Latvia||Latvia||Presentation at the 6th International Nurse Forum, July 2015||560||34,71|
|PHA Latvia||Latvia||Presentation at the 6th International Nurse Forum, July 2015||560||13,45|
|Sarcoma Patients EuroNet Association (SPAEN)||Germany||Support of PO regarding their core and project activities in 2015, including the SPAEN Annual Conference, and objective patient education activities||22,000||no|
|Stroke Alliance for Europe (SAFE)||UK||Sponsorship of the SAFE Working Conference and General Assembly 2015||75,460||no|
|Union for International Cancer Control (UICC)||Switzerland||Support of PO in a partnership agreement for the years 2015, with support of UICC advocacy program, incl. initiatives such as World Cancer Day, World Cancer Congress, Leaders' Summit and various objective workshop meetings||22,196||no|
|Baltic States||Reports can be received from||UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
|Belgium/Luxemburg (French)||Country website|
|Belgium/Luxemburg (Dutch)||Country website|
|Czech Republic||Country website|
|Estonia||Reports can be received from||UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
|Iceland||Reports can be received from||Bayer AB- Bayer Scandinavia
Gustav III:s Boulevard 56
169 26 Solna
|Romania||Reports can be received from||SC Bayer SRL
Bayer Pharmaceuticals Division
Sos. Pipera nr. 42., Sector 2
NUSCO Tower fl. 1,16,17
|Serbia||Reports can be received from||Bayer Pharma d.o.o.
Omladinskih brigada 88b
|Slovenia||Reports can be received from||Bayer d.o.o.
Lucija Zlodi Gosnik
Donations in Germany
Social responsibility is at the core of Bayer’s identity. For us, donations are an effective way of expressing this responsibility and engaging in social action. Bayer provides financial resources and donations of drugs and cash to support projects worldwide dealing with health and scientific research.
We have published a list of projects that Bayer and its cooperating companies supported with donations in 2015. We published this list in compliance with the code of conduct of the association Voluntary Self-Regulation of the Pharmaceutical Industry ("Freiwillige Selbstkontrolle für die Arzneimittelindustrie"). Since the legally required disclosures are specific German requirements, the list of projects is only available in German: http://www.gesundheit.bayer.de/de/engagement/patientenorganisationen/projekte/index.php